Press release
DHODH Inhibitor Pipeline Drugs Report 2025: Comprehensive Analysis of Drug Development, Clinical Trials, and Strategic Industry Outlook
Curious about the latest updates in the DHODH Inhibitor Pipeline? Click here to explore the therapies and trials making headlines @ DHODH Inhibitor Pipeline Outlook Report [https://www.delveinsight.com/sample-request/dihydroorotate-dehydrogenase-dhodh-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the DHODH Inhibitor Pipeline Report
* DelveInsight's DHODH Inhibitor Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for DHODH Inhibitor treatment.
* The leading DHODH Inhibitor Companies, such as Sanofi, Immunic, PTC Therapeutics, Clear Creek Bio, EyeGate Pharma, ASLAN Pharmaceuticals, Medicines for Malaria Venture, and others.
* Promising DHODH Inhibitor Therapies such as RP7214, IMU-838, PTC 299, and others.
Want to know which companies are leading innovation in DHODH Inhibitor? Dive into the full pipeline insights @ DHODH Inhibitor Clinical Trials Assessment [https://www.delveinsight.com/sample-request/dihydroorotate-dehydrogenase-dhodh-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The DHODH Inhibitor Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The DHODH Inhibitor Pipeline Report also highlights the unmet needs with respect to the DHODH Inhibitor.
DHODH Inhibitor Overview
Dihydroorotate dehydrogenase (DHODH), a novel enzyme, involved in the biosynthesis of uridine. Dihydroorotate dehydrogenases are grouped into Class 1 and Class 2, according to sequence similarity, subcellular location and substrate preference. This protein is a mitochondrial protein located on the outer surface of the inner mitochondrial membrane (IMM). DHODH enzyme is proven to play an active role in cancer and immunological disorders such as Acute Myeloid Leukemia, Rheumatoid Arthritis, and Multiple Sclerosis. Inhibitors of DHODH block the synthesis of pyrimidine-based nucleotides and are known to potentially possess wide applications as chemotherapeutic agents. Suppression of the DHODH enzyme in humans is a proven treatment method for immune disorders, especially cancer, RA (Leflunomide) and multiple sclerosis (Teriflunomide). There are a number of clinical trials underway for COVID-19 Treatment using DHODH inhibitors.
DHODH Inhibitor Emerging Drugs Profile
* IMU-838: Immunic
IMU-838 is a small molecule, oral tablet formulation based investigational drug that inhibits dihydroorotate dehydrogenase (DHODH) enzyme. IMU-838 is under clinical development for the treatment of relapsing-remitting multiple sclerosis, or RRMS, inflammatory bowel disease, or IBD, and other chronic inflammatory and autoimmune diseases. The drug is in Phase II/III clinical evaluation for the treatment of COVID 2019 infections.
* PTC 299: PTC Therapeutics
Emvododstat (formerly PTC 299) is an oral, small molecule tablet that inhibits the cellular enzyme DHODH. The drug is in Phase II/III clinical studies for COVID 2019 infections and in Phase I for Acute myeloid leukaemia.
If you're tracking ongoing DHODH Inhibitor Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ DHODH Inhibitor Treatment Drugs [https://www.delveinsight.com/sample-request/dihydroorotate-dehydrogenase-dhodh-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The DHODH Inhibitor Pipeline report provides insights into:-
* The report provides detailed insights about companies that are developing therapies for the treatment of DHODH Inhibitor with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for DHODH Inhibitor Treatment.
* DHODH Inhibitor Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* DHODH Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the DHODH Inhibitor market.
DHODH Inhibitor Companies
Sanofi, Immunic, PTC Therapeutics, Clear Creek Bio, EyeGate Pharma, ASLAN Pharmaceuticals, Medicines for Malaria Venture and others.
DHODH Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Oral
* Parenteral
* Subcutaneous
* Topical
* Molecule Type
DHODH Inhibitor Products have been categorized under various Molecule types such as
* Vaccines
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Product Type
From emerging drug candidates to competitive intelligence, the DHODH Inhibitor Pipeline Report covers it all - check it out now @ DHODH Inhibitor Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/dihydroorotate-dehydrogenase-dhodh-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the DHODH Inhibitor Pipeline Report
* Coverage- Global
* DHODH Inhibitor Companies- Sanofi, Immunic, PTC Therapeutics, Clear Creek Bio, EyeGate Pharma, ASLAN Pharmaceuticals, Medicines for Malaria Venture and others.
* DHODH Inhibitor Therapies- RP7214, IMU-838, PTC 299 , and others.
* DHODH Inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* DHODH Inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the DHODH Inhibitor Treatment landscape in this detailed analysis @ DHODH Inhibitor Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/dihydroorotate-dehydrogenase-dhodh-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Dihydroorotate Dehydrogenase (DHODH) Inhibitor: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Dihydroorotate Dehydrogenase (DHODH) Inhibitor - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Dihydroorotate Dehydrogenase (DHODH) Inhibitor Collaboration Deals
* Late Stage Products (Phase III)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II/III)
* IMU-838: Immunic
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* PP 001: EyeGate Pharma
* Drug profiles in the detailed report.....
* Pre-clinical and Discovery Stage Products
* MMV-1793609: Medicines for Malaria Venture
* Drug profiles in the detailed report.....
* Inactive Products
* Dihydroorotate Dehydrogenase (DHODH) Inhibitor Key Companies
* Dihydroorotate Dehydrogenase (DHODH) Inhibitor Key Products
* Dihydroorotate Dehydrogenase (DHODH) Inhibitor- Unmet Needs
* Dihydroorotate Dehydrogenase (DHODH) Inhibitor- Market Drivers and Barriers
* Dihydroorotate Dehydrogenase (DHODH) Inhibitor- Future Perspectives and Conclusion
* Dihydroorotate Dehydrogenase (DHODH) Inhibitor Analyst Views
* Dihydroorotate Dehydrogenase (DHODH) Inhibitor Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dhodh-inhibitor-pipeline-drugs-report-2025-comprehensive-analysis-of-drug-development-clinical-trials-and-strategic-industry-outlook]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/dihydroorotate-dehydrogenase-dhodh-inhibitor-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release DHODH Inhibitor Pipeline Drugs Report 2025: Comprehensive Analysis of Drug Development, Clinical Trials, and Strategic Industry Outlook here
News-ID: 4204547 • Views: …
More Releases from ABNewswire
Enhance Home Interiors with Quality Skirting Boards
For those looking to upgrade their interiors, investing in quality skirting boards is a simple yet effective way to transform a room. From protecting walls to enhancing aesthetics, skirting boards play a crucial role in creating polished, sophisticated, and functional living spaces.
In modern interior design, small details can make a significant impact on the overall look and feel of a home. One such detail that combines functionality and aesthetic appeal…
Experience the Ultimate Adventure at a Costa Rica Surf Camp
For those seeking a mix of thrill, relaxation, and cultural exploration, a Costa Rica surf camp offers an unparalleled experience. It's more than learning to surf-it's about connecting with nature, discovering new skills, and creating lifelong friendships. Whether it's your first time on a board or you're looking to refine your technique, Costa Rica's surf camps promise an adventure you won't soon forget.
Costa Rica, known for its lush rainforests, stunning…
Diffuse Large B Cell Lymphoma Pipeline Drugs Report 2025: Tracking Novel Therapi …
DelveInsight's "Diffuse Large B Cell Lymphoma Pipeline Insight 2025" report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in the Diffuse Large B Cell Lymphoma pipeline landscape. It covers the Diffuse Large B Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diffuse Large B Cell Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further…
Huntington's Disease Pipeline Drugs Report 2025: Unveiling the Future of Therape …
DelveInsight's "Huntington's Disease Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Huntington's Disease pipeline landscape. It covers the Huntington's Disease Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Huntington's Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a sample and discover…
More Releases for DHODH
Relapsing-Remitting Multiple Sclerosis Pipeline Insight 2025: Advancing Toward R …
Relapsing-Remitting Multiple Sclerosis (RRMS), the most common MS form, drives active R&D as companies seek safer, more effective, and potentially curative therapies. Affecting 85% of initial MS cases, RRMS involves episodic neurological symptoms with recovery periods. While current disease-modifying therapies (DMTs) like ocrelizumab and fingolimod offer expanded options, challenges remain in long-term efficacy, safety, and halting disease progression.
DelveInsight's "Relapsing-Remitting Multiple Sclerosis - Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/relapsing-remitting-multiple-sclerosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]" reveals a vibrant pipeline…
Relapsing-Remitting Multiple Sclerosis Pipeline Appears Robust With 20+ Key Phar …
DelveInsight's, "Relapsing-Remitting Multiple Sclerosis Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Relapsing-Remitting Multiple Sclerosis pipeline landscape. It covers the Relapsing-Remitting Multiple Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Relapsing-Remitting Multiple Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with…
Smartphone Display Driver Market Overview: Segmentation Analysis, Growth Trends …
Smartphone Display Driver Market Insights: Trends, Drivers, and Outlook 2024 - 2031
Smartphone Display Driver Market Scope: Unveiling Today's Trends
A Smartphone Display Driver is a critical component that manages the display's functionality and visual output in smartphones. The Smartphone Display Driver market has experienced significant growth driven by the increasing demand for high-resolution displays and advancements in display technologies, such as OLED and AMOLED. As smartphones become equipped with larger and…
Intra Aortic Counterpulsation Device Market Size 2024 to 2031.
Market Overview and Report Coverage
An intra-aortic counterpulsation device is a mechanical pump that helps improve heart function by increasing blood flow to the coronary arteries. This device is commonly used in patients with severe heart failure or after a heart attack to reduce the workload of the heart and improve cardiac output.
The future outlook for the intra-aortic counterpulsation device market looks promising, with a projected growth rate of…
Next Generation Neurofeedback Devices Market Size 2024 to 2031.
Market Overview and Report Coverage
Next Generation Neurofeedback Devices are advanced technological tools used to monitor and regulate brain activity through real-time feedback. These devices are commonly used in the fields of psychology, neuroscience, and mental health to help individuals improve their cognitive functions, manage stress, and treat various neurological disorders.
The current outlook of the Next Generation Neurofeedback Devices Market is quite promising, with a projected growth rate of…
Industrial Soda Ash Market Outlook 2031 Data By Key Players-Solvay SA, Genesis A …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to 𝐌𝐑𝐈, the global Industrial Soda Ash Market size in terms of revenue was valued at around USD XX.X billion in 2023 and is expected to reach a value of 𝐔𝐒𝐃 𝐗𝐗.𝐗 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟏, growing at a 𝐂𝐀𝐆𝐑 𝐨𝐟 𝐫𝐨𝐮𝐠𝐡𝐥𝐲 𝐗𝐗.𝐗% 𝐟𝐫𝐨𝐦 𝟐𝟎𝟐𝟒 𝐭𝐨 𝟐𝟎𝟑𝟏. The global Industrial Soda Ash market is projected to grow at a significant growth rate due to several driving factors.
Due to its vital role in numerous…
